近日,康诺亚发布2026年半年度业绩预告,公司预计中期净利润不低于12亿元,系出售Ouro Medicines股权收益16.8亿元计入所致。值得注意的是,该公司2025年同期亏损约7900万元。 据公告披露的利润来源细项,包括不可持续资产出售、主营业务收入、合作收入。其中,资产出售收益16.8亿元,核心产品销售收入3.9亿元,CMG901里程碑付款约2.2亿元。计算比例可知,利润的八成贡献来自...
Source Link近日,康诺亚发布2026年半年度业绩预告,公司预计中期净利润不低于12亿元,系出售Ouro Medicines股权收益16.8亿元计入所致。值得注意的是,该公司2025年同期亏损约7900万元。 据公告披露的利润来源细项,包括不可持续资产出售、主营业务收入、合作收入。其中,资产出售收益16.8亿元,核心产品销售收入3.9亿元,CMG901里程碑付款约2.2亿元。计算比例可知,利润的八成贡献来自...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.